卡培他滨-话题@MedSci

#卡培他滨#

72篇内容 | 4559人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1293515, encodeId=e691129351541, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=Lancet oncol：Tucatinib联合卡培他滨、曲妥珠单抗治疗HER2阳性的进展期乳腺癌患者，毒副作用可接受，且具有抗肿瘤效果, objectType=article, longId=139112, objectId=33c3139112e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33c3139112e3, replyNumber=0, likeNumber=89, createdTime=2018-05-27, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33c3139112e3, moduleTitle=Lancet oncol：Tucatinib联合卡培他滨、曲妥珠单抗治疗HER2阳性的进展期乳腺癌患者，毒副作用可接受，且具有抗肿瘤效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33c3139112e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293514, encodeId=d58412935143e, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=EUR J Cancer：卡培他滨联合贝伐单抗在转移性结直肠癌维持治疗中的成本效益分析, objectType=article, longId=125182, objectId=26791251825d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26791251825d, replyNumber=0, likeNumber=98, createdTime=2018-01-01, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26791251825d, moduleTitle=EUR J Cancer：卡培他滨联合贝伐单抗在转移性结直肠癌维持治疗中的成本效益分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26791251825d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293513, encodeId=1f3b1293513b9, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=EUR J Cancer：放疗联合卡培他滨和索拉非尼治疗晚期KRAS突变的直肠癌：I / II期临床试验（SAKK 41/08）, objectType=article, longId=124481, objectId=c81c12448125, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c81c12448125, replyNumber=0, likeNumber=86, createdTime=2017-12-26, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c81c12448125, moduleTitle=EUR J Cancer：放疗联合卡培他滨和索拉非尼治疗晚期KRAS突变的直肠癌：I / II期临床试验（SAKK 41/08）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c81c12448125)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293512, encodeId=3458129351289, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=Lancet Gastroen Hepatol：III级结肠癌患者的辅助治疗——氟尿嘧啶S1vs卡培他滨, objectType=article, longId=117531, objectId=fad311e53132, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fad311e53132, replyNumber=0, likeNumber=0, createdTime=2017-10-27, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fad311e53132, moduleTitle=Lancet Gastroen Hepatol：III级结肠癌患者的辅助治疗——氟尿嘧啶S1vs卡培他滨, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fad311e53132)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293511, encodeId=9afb12935114f, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=JAMA Oncol：指纹就这样在接受卡培他滨化疗后消失了……我是谁？, objectType=article, longId=108837, objectId=76ff10883ec0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76ff10883ec0, replyNumber=0, likeNumber=93, createdTime=2017-08-16, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76ff10883ec0, moduleTitle=JAMA Oncol：指纹就这样在接受卡培他滨化疗后消失了……我是谁？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76ff10883ec0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293510, encodeId=5fe41293510c3, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=Lancet Oncol:表阿霉素/顺铂/卡培他滨新辅助治疗食管腺癌并不优于标准治疗, objectType=article, longId=108311, objectId=a8c210831193, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8c210831193, replyNumber=0, likeNumber=84, createdTime=2017-08-11, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8c210831193, moduleTitle=Lancet Oncol:表阿霉素/顺铂/卡培他滨新辅助治疗食管腺癌并不优于标准治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8c210831193)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293509, encodeId=dc0012935098e, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=Lancet oncol：食管腺癌术前行新辅助化疗顺铂联合氟尿嘧啶与表柔比星、顺铂联合卡培他滨的疗效对比。, objectType=article, longId=107807, objectId=d5be10e807c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5be10e807c3, replyNumber=0, likeNumber=65, createdTime=2017-08-06, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5be10e807c3, moduleTitle=Lancet oncol：食管腺癌术前行新辅助化疗顺铂联合氟尿嘧啶与表柔比星、顺铂联合卡培他滨的疗效对比。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d5be10e807c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293508, encodeId=141512935087a, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=JAMA Oncology：维生素B6不能预防卡培他滨引起的手足综合征, objectType=article, longId=105570, objectId=eafd1055e000, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eafd1055e000, replyNumber=0, likeNumber=94, createdTime=2017-07-16, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eafd1055e000, moduleTitle=JAMA Oncology：维生素B6不能预防卡培他滨引起的手足综合征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eafd1055e000)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293507, encodeId=4234129350eb3, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=SCI REP：卡培他滨和紫杉醇治疗转移性胰腺癌患者总体生存率的生化和遗传预测因子！, objectType=article, longId=105032, objectId=80fb105032bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=80fb105032bc, replyNumber=0, likeNumber=73, createdTime=2017-07-10, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=80fb105032bc, moduleTitle=SCI REP：卡培他滨和紫杉醇治疗转移性胰腺癌患者总体生存率的生化和遗传预测因子！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=80fb105032bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293506, encodeId=3c18129350600, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=JAMA Oncology：卡培他滨联合多西他赛、表柔比星以及环磷酰胺进行早期乳腺癌新辅助治疗, objectType=article, longId=104744, objectId=68dd104e44bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68dd104e44bd, replyNumber=0, likeNumber=106, createdTime=2017-07-07, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68dd104e44bd, moduleTitle=JAMA Oncology：卡培他滨联合多西他赛、表柔比星以及环磷酰胺进行早期乳腺癌新辅助治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=68dd104e44bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293505, encodeId=48ca12935050a, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=JAMA Oncology：晚期胃食管交界处肿瘤卡培他滨疗效与质子泵抑制剂之间的关系, objectType=article, longId=104742, objectId=5769104e42a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5769104e42a9, replyNumber=0, likeNumber=84, createdTime=2017-07-07, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5769104e42a9, moduleTitle=JAMA Oncology：晚期胃食管交界处肿瘤卡培他滨疗效与质子泵抑制剂之间的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5769104e42a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293504, encodeId=a89512935044e, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=New Engl J Med ：乳腺癌患者福音:卡培他滨对于棘手的乳腺癌效果神奇！, objectType=article, longId=100669, objectId=450210066956, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=450210066956, replyNumber=0, likeNumber=97, createdTime=2017-06-05, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=450210066956, moduleTitle=New Engl J Med ：乳腺癌患者福音:卡培他滨对于棘手的乳腺癌效果神奇！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=450210066956)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293503, encodeId=c77a12935035a, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=NEJM：卡培他滨用于HER2阴性侵袭性乳腺癌, objectType=article, longId=100383, objectId=5ff6100383d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ff6100383d7, replyNumber=0, likeNumber=90, createdTime=2017-06-03, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ff6100383d7, moduleTitle=NEJM：卡培他滨用于HER2阴性侵袭性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ff6100383d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293502, encodeId=292d129350239, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=Lancet：胰腺癌手术切除的患者：辅助吉西他滨+卡培他滨vs吉西他滨单药, objectType=article, longId=97105, objectId=a68e9e10542, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a68e9e10542, replyNumber=0, likeNumber=101, createdTime=2017-04-27, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a68e9e10542, moduleTitle=Lancet：胰腺癌手术切除的患者：辅助吉西他滨+卡培他滨vs吉西他滨单药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a68e9e10542)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293501, encodeId=1a961293501a3, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=The Lancet Gastroenterology & Hepatology：veliparib联合卡培他滨加放疗治疗晚期直肠癌的安全性, objectType=article, longId=93776, objectId=2b1b93e7645, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b1b93e7645, replyNumber=0, likeNumber=88, createdTime=2017-03-30, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b1b93e7645, moduleTitle=The Lancet Gastroenterology & Hepatology：veliparib联合卡培他滨加放疗治疗晚期直肠癌的安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b1b93e7645)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293500, encodeId=b615129350006, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=LANCET：吉西他滨+卡培他滨vs.吉西他滨单一给药在胰腺癌切除术后的疗效, objectType=article, longId=88165, objectId=e27d881657b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e27d881657b, replyNumber=0, likeNumber=89, createdTime=2017-02-01, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e27d881657b, moduleTitle=LANCET：吉西他滨+卡培他滨vs.吉西他滨单一给药在胰腺癌切除术后的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e27d881657b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293499, encodeId=acba1293499a2, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=Lancet Oncol：HER2-乳癌患者：贝伐单抗+卡培他滨 vs 贝伐单抗+紫杉醇(TURANDOT), objectType=article, longId=76930, objectId=9a94e693000, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a94e693000, replyNumber=0, likeNumber=48, createdTime=2016-09-09, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a94e693000, moduleTitle=Lancet Oncol：HER2-乳癌患者：贝伐单抗+卡培他滨 vs 贝伐单抗+紫杉醇(TURANDOT), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a94e693000)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293498, encodeId=5c4f129349870, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=服用卡培他滨，你可能不了解的几个细节, objectType=article, longId=71248, objectId=d451e1248ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d451e1248ed, replyNumber=0, likeNumber=70, createdTime=2016-06-21, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d451e1248ed, moduleTitle=服用卡培他滨，你可能不了解的几个细节, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d451e1248ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293497, encodeId=1859129349e79, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=JCO：拉帕替尼联用卡培他滨和奥沙利铂并不延长胃癌患者总生存时间, objectType=article, longId=60099, objectId=b5e3600995e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b5e3600995e, replyNumber=0, likeNumber=76, createdTime=2015-12-05, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b5e3600995e, moduleTitle=JCO：拉帕替尼联用卡培他滨和奥沙利铂并不延长胃癌患者总生存时间, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b5e3600995e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1293496, encodeId=00f81293496b5, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, objectTitle=招募患者：马来酸吡咯替尼片联合卡培他滨对比拉帕替尼联合卡培他滨治疗HER2表达阳性转移性乳腺癌的I/II期临床研究, objectType=article, longId=56015, objectId=17c9560153c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17c9560153c, replyNumber=0, likeNumber=84, createdTime=2015-09-11, rootId=0, userName=w363522449, userId=1c8c241, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17c9560153c, moduleTitle=招募患者：马来酸吡咯替尼片联合卡培他滨对比拉帕替尼联合卡培他滨治疗HER2表达阳性转移性乳腺癌的I/II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17c9560153c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

卡培他滨

2020-05-29

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

Lancet oncol：Tucatinib联合卡培他滨、曲妥珠单抗治疗HER2阳性的进展期乳腺癌患者，毒副作用可接受，且具有抗肿瘤效果

2018-05-27

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

EUR J Cancer：卡培他滨联合贝伐单抗在转移性结直肠癌维持治疗中的成本效益分析

2018-01-01

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

EUR J Cancer：放疗联合卡培他滨和索拉非尼治疗晚期KRAS突变的直肠癌：I / II期临床试验（SAKK 41/08）

2017-12-26

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

Lancet Gastroen Hepatol：III级结肠癌患者的辅助治疗——氟尿嘧啶S1vs卡培他滨

2017-10-27

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

JAMA Oncol：指纹就这样在接受卡培他滨化疗后消失了……我是谁？

2017-08-16

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

Lancet Oncol:表阿霉素/顺铂/卡培他滨新辅助治疗食管腺癌并不优于标准治疗

2017-08-11

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

Lancet oncol：食管腺癌术前行新辅助化疗顺铂联合氟尿嘧啶与表柔比星、顺铂联合卡培他滨的疗效对比。

2017-08-06

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

JAMA Oncology：维生素B6不能预防卡培他滨引起的手足综合征

2017-07-16

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

SCI REP：卡培他滨和紫杉醇治疗转移性胰腺癌患者总体生存率的生化和遗传预测因子！

2017-07-10

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

JAMA Oncology：卡培他滨联合多西他赛、表柔比星以及环磷酰胺进行早期乳腺癌新辅助治疗

2017-07-07

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

JAMA Oncology：晚期胃食管交界处肿瘤卡培他滨疗效与质子泵抑制剂之间的关系

2017-07-07

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

New Engl J Med ：乳腺癌患者福音:卡培他滨对于棘手的乳腺癌效果神奇！

2017-06-05

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

NEJM：卡培他滨用于HER2阴性侵袭性乳腺癌

2017-06-03

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

Lancet：胰腺癌手术切除的患者：辅助吉西他滨+卡培他滨vs吉西他滨单药

2017-04-27

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

The Lancet Gastroenterology & Hepatology：veliparib联合卡培他滨加放疗治疗晚期直肠癌的安全性

2017-03-30

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

LANCET：吉西他滨+卡培他滨vs.吉西他滨单一给药在胰腺癌切除术后的疗效

2017-02-01

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

Lancet Oncol：HER2-乳癌患者：贝伐单抗+卡培他滨 vs 贝伐单抗+紫杉醇(TURANDOT)

2016-09-09

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

服用卡培他滨，你可能不了解的几个细节

2016-06-21

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

JCO：拉帕替尼联用卡培他滨和奥沙利铂并不延长胃癌患者总生存时间

2015-12-05

w363522449 (审核中...)

前往app查看评论内容

#卡培他滨#

招募患者：马来酸吡咯替尼片联合卡培他滨对比拉帕替尼联合卡培他滨治疗HER2表达阳性转移性乳腺癌的I/II期临床研究

2015-09-11

科室
- - 订阅+
  - 更多科室
工具
服务